Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...

周四，Leerink Partners维持了对制药巨头礼来（NYSE:LLY）的"跑赢大市"评级和990.00美元的目标价。该公司的立场是基于英国最近的动向，英国计划评估礼来的药物tirzepatide对肥胖症造成的经济压力的影响。

Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...